Patch for at-home use detects sleep apnea

Researchers have developed a wearable patch to diagnose obstructive sleep apnea at all severity levels. Researchers, who published findings in Sleep, aimed to create a cost-effective, lightweight wearable to monitor patients without disrupting sleep patterns.

Current home sleep monitors often disrupt patients, making them less accurate. The SomnaPatch weighs less than an ounce and can be easily set up by patients in their home.

Able to record nasal pressure, blood oxygen saturation, pulse rate, respiratory effort, sleep time and body position, the SomnaPatch was compared in effectiveness with standard in-lab polysomnography. Some 174 patients were recorded for simultaneously polysomnography and patch recordings and then auto-scored by Somnolyzer software.

Results showed the patch and lab polysomnography had a total rate of clinical agreement at 87.4 percent, with a 95 percent confidence interval of 81.4 percent to 91.9 percent. Additionally, home usability rates found 38 out of 39 users were successful in activating the patch and recording four hours of sleep data.

"Our study provided clinical validation of a new wearable device for diagnosing sleep apnea," said principal investigator Maria Merchant, PhD, CEO of Somnarus. "It was most surprising to us how well this inexpensive miniature device performed in comparison with in-lab sleep studies. Most home sleep diagnostic devices are difficult for patients to use and are disruptive to patient's sleep. Our study showed that this wearable home sleep monitor is very comfortable, easy to use and does not negatively affect sleep."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup